To investigate the application status of anti-tumor adjutant drugs in Anhui Provincial Cancer Hospital ( hereinafter referred to as“our hospital”) , so as to provide reference for the standardization application in clinic and reduce the burden on patients.METHODS: Based on clinical pharmacy management system ( PASS ) , the top five anti-tumor adjutant drugs ranked by consumption sum from Oct.to Dec.2015 were collected, analysis was conducted on the application rationality of the randomly selected drug categories(50 cases each).RESULTS:The top five anti-tumor adjutant drugs ranked by consumption sum were respectively Recombinant human interleukin-2 injections, Aidi injections, Recombinant human colony-stimulating factor injections, Granisetron hydrochloride injections and omeprazole sodium for injection.Of the 250 cases with the five drugs, 73 cases were irrational drug use, the irrational rate was 29.20%; the irrational drug use were mainly performed as over treatment course, over indications, over maximum dose and inappropriate solvent, etc..CONCLUSIONS: There are still some irrational phenomenon in the application of anti-tumor adjutant drugs.It is necessary to strengthen the administration intervention and standardize the clinical application of anti-tumor adjutant drugs.%目的：了解安徽省肿瘤医院（以下简称“我院”）抗肿瘤辅助用药的使用情况，为临床规范使用该类药物提供参考，以减轻患者就医负担。方法：通过临床药学管理系统，统计出2015年10—12月我院销售金额排序居前5位的抗肿瘤辅助用药，并对随机抽取的使用相应品种的各50例患者的用药合理性进行分析。结果：我院销售金额排序居前5位的抗肿瘤辅助用药分别为重组人白细胞介素2注射液、艾迪注射液、重组人粒细胞集落刺激因子注射液、盐酸格拉司琼注射液及注射用奥美拉唑钠。抽查的250例使用这5种药品的患者中，共73例存在不合理用药，不合理用药率为29.20％；不合理用药主要表现为超疗程用药、超适应证用药、超剂量用药、溶剂不适宜等。结论：我院抗肿瘤辅助用药存在不合理使用的现象，应加强用药干预，规范抗肿瘤辅助用药的临床应用。
展开▼
